Ono Pharmaceutical said on August 1 that it has entered into a new option and research collaboration accord with Australia’s Monash University to discover and develop new antibodies targeting G protein-coupled receptors (GPCRs) for autoimmune and inflammatory diseases. In January…
To read the full story
Related Article
- Ono, Monash University Ink GPCR Antibody Deal
January 16, 2023
BUSINESS
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
- Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
- Xospata Misses OS Endpoint in PIII Trial in Untreated FLT3-Mutated AML
March 10, 2026
- Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





